The Alzforum team compiles some of their favorite stories from the past year.
Bayesian adaptive Phase 2 trial of anti-protofibril Aβ antibody did not, as desired, deliver an accelerated result. It will now continue to its end at 18 months.
At SfN 2017, some of the lesser-known tau toxicities came in for deep scrutiny.
At SfN 2017, scientists advanced the idea that bacteria teeming in a person’s digestive tract could influence both pathology and symptoms of diseases such as Alzheimer’s.
Why, hello tau! Convergence of PET and EEG research affirms that sleeping well is crucial to memory consolidation and curbing Alzheimer’s-related proteins.
Tau Snapshots from Neuroscience 2017 Disturbed Sleep Exerts Toll on Memory and Neurodegeneration Gut Microbiome May Modify Neurodegeneration This year’s annual meeting drew more than 23,000 scientists and featured 1,000 presentations on Alzheimer’s ...
Novel ways to control tau captured the imaginations of scientists at the Society for Neuroscience annual meeting.
Using CRISPR for the first time in a model of ALS, researchers dampened expression of mutant SOD1 in mouse motor neurons
Protein bundles released by microglia, called ASC specks, seed Aβ aggregates in vitro and in vivo.
The new ACTC network will establish streamlined recruitment and startup protocols to make trials more efficient.
Certified reference material by which companies can calibrate assays is now available worldwide.
At recent CTAD conference, Rachelle Doody called on her colleagues to learn from failures and work together to support better drug evaluation studies.
The GWAS confirms known associations, and hints at new ones. It suggests DLB is genetically distinct from AD or PD.
Null results ended the development of the neuroprotective drugs edonerpic and abeotaxane, the AMPA receptor modulator S47445, and the dietary formulation tricaprilin.
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.